報價延遲最少15分鐘:2025/02/22 18:07 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.35 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.75/1.37
|
|
企業價值
19.39M
|
| 資產負債 |
|
每股賬面淨值
4.99
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
81.00M
|
|
每股收益
17.41
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/22 18:07 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidityand a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment. |